Takhzyro Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing diagnosis of hereditary angioedema, availability of targeted kallikrein inhibitors, expansion of specialty care centers, growing awareness of rare disease management, reimbursement support for orphan drugs.

The growth in the forecast period can be attributed to increasing investments in rare disease therapeutics, rising demand for patient-friendly biologics, expansion of personalized medicine approaches, growing focus on long-term disease prevention, increasing innovation in monoclonal antibody engineering. Major trends in the forecast period include increasing adoption of long-acting hae prophylactic therapies, rising use of monoclonal antibodies in rare diseases, expansion of self-administered injectable treatments, growing focus on preventive hae management, improved patient adherence through extended dosing.

The increasing prevalence of hereditary angioedema (HAE) is expected to drive the growth of the Takhzyro market in the coming years. Hereditary angioedema (HAE) is a rare genetic disorder marked by recurrent and severe swelling in various parts of the body, including the airway, which can be life-threatening. The rise in HAE cases is linked to improved awareness, advances in genetic testing, and identification of spontaneous mutations in the C1 inhibitor gene, along with environmental triggers. Takhzyro (lanadelumab) helps prevent HAE attacks by inhibiting kallikrein, reducing bradykinin levels, and decreasing the frequency and severity of swelling episodes. For example, in January 2025, PubMed reported that the pooled prevalence of HAE was 1.22 cases per 100,000 people, with HAE type 1 accounting for the majority and a slight female predominance. Therefore, the prevalence of hereditary angioedema (HAE) is fueling the growth of the Takhzyro market.

The rising healthcare expenditure is also contributing significantly to the growth of the Takhzyro market. Healthcare expenditure encompasses the total financial resources spent on medical services, treatments, and related activities over a specific period. Growth in healthcare spending is driven by factors such as an aging population, chronic disease prevalence, rising healthcare costs, technological advancements, and medical inflation. Increased expenditure enables broader access to effective therapies like Takhzyro, supporting pricing and cost-effectiveness considerations in the market. For instance, in November 2025, the OECD reported that in 2024, member countries allocated an average of around 9.3% of their GDP to health. Therefore, rising healthcare expenditure is driving the growth of the Takhzyro market.

Major companies in the Takhzyro market are focusing on developing advanced pediatric prophylaxis treatments to prevent HAE attacks in both adults and children. Prophylaxis involves preventive interventions aimed at reducing disease risk by administering medications before episodes occur. For example, in February 2023, Takeda Pharmaceutical Company, a Japan-based biopharmaceutical firm, announced that the U.S. FDA approved a supplemental biologics license application (sBLA) for expanded use of Takhzyro (lanadelumab-flyo) for prophylaxis in pediatric patients aged 2 to under 12 years. This approval was supported by extrapolated efficacy data from the HELP Study, a Phase 3 trial involving patients aged 12 to under 18 years.

Major companies operating in the takhzyro market are Takeda Pharmaceuticals Inc.

North America was the largest region in the takhzyro market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the takhzyro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the takhzyro market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the takhzyro market by increasing costs of imported biologic raw materials, injectable delivery components, sterile manufacturing supplies, and cold-chain logistics services. North America and Europe are most affected due to reliance on international biologics supply chains, while Asia-Pacific faces higher distribution and storage costs. These tariffs are contributing to elevated therapy costs and supply chain complexity. However, they are also encouraging domestic biologics production, regional fill-finish capacity expansion, and long-term supply security for rare disease treatments.

The takhzyro market research report is one of a series of new reports that provides takhzyro market statistics, including takhzyro industry global market size, regional shares, competitors with a takhzyro market share, detailed takhzyro market segments, market trends and opportunities, and any further data you may need to thrive in the takhzyro industry. This takhzyro market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Takhzyro (lanadelumab-flyo) is a prescription medication used to prevent attacks of hereditary angioedema (HAE) in individuals aged 2 years and older. It is a monoclonal antibody that inhibits plasma kallikrein, lowering bradykinin levels and reducing the frequency and severity of swelling episodes associated with HAE.

The primary indications for Takhzyro include HAE prophylaxis, treatment of acute HAE attacks, and other related uses. HAE prophylaxis refers to preventive therapy aimed at decreasing the frequency and severity of angioedema attacks in affected individuals. Takhzyro is distributed through hospital pharmacies, retail pharmacies, and online pharmacies and is used by pediatric, adult, and geriatric patients.

The takhzyro market consists of sales of single-dose prefilled syringes, single-dose vials, and ready-to-use solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.